Savara (SVRA) Preferred Dividend Payments (2010 - 2017)
Savara (SVRA) posted quarterly Preferred Dividend Payments of $554000.0 for Q2 2017, up 27600.0% year-over-year from N/an in Q2 2016, and up 2208.33% quarter-over-quarter from $24000.0 in Q1 2017.
Powered by 
Analysis
Savara (SVRA) Preferred Dividend Payments (2010 - 2017) Analysis & Trends
Savara (SVRA) has reported Preferred Dividend Payments for 3 consecutive years, with $554000.0 the latest figure, recorded in Q2 2017.
- In Q2 2017, Preferred Dividend Payments rose 27600.0% year-over-year to $554000.0; the TTM figure through Dec 2017 stood at $578000.0 (down 94.91% YoY), while the FY2017 annual figure was $578000.0, up 514.89% from the prior year.
- Preferred Dividend Payments grew to $554000.0 in Q2 2017 per SVRA's latest filing, from $24000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $554000.0 in Q2 2017 and bottomed at $2000.0 in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | 554,000.00 |
| Mar 31, 2017 | 24,000.00 |
| Dec 31, 2016 | 24,000.00 |
| Sep 30, 2016 | 44,000.00 |
| Jun 30, 2016 | 2,000.00 |
| Dec 31, 2010 | 11.28 Mn |
| Jun 30, 2010 | -3.12 Mn |